Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 326, Issue 1, 2008, Pages 259-269

  Popelová, Olga ^a   Štěrba, Martin ^a   Šimůnek, Tomáš ^b   Mazurová, Yvona ^a   Gunčová, Ivana ^a   Hroch, Miloš ^a   Adamcová, Michaela ^a   Geršl, Vladimír ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DEFERIPRONE; MALONALDEHYDE; TROPONIN T;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARDIOTOXICITY; CHRONIC TOXICITY; CONTROLLED STUDY; DRUG ANTAGONISM; HEART DISEASE; HEART LEFT VENTRICLE; HEART PROTECTION; HUMAN; HUMAN CELL; LIPID PEROXIDATION; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RABBIT;

ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CARDIOTONIC AGENTS; CELL PROLIFERATION; DAUNORUBICIN; HEART DISEASES; HL-60 CELLS; HUMANS; MALE; PYRIDONES; RABBITS;

EID: 45749156776     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.137604     Document Type: Article

References (46)

1. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, and Pennell DJ (2002) Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 360:516-520.
2. Barnabé N, Zastre JA, Venkataram S, and Hasinoff BB (2002) Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radic Biol Med 33:266-275.
3. Bast A, Haenen GR, Bruynzeel AM, and Van der Vijgh WJ (2007) Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials. Cardiovasc Toxicol 7:154-159.
4. Chen B, Peng X, Pentassuglia L, Lim CC, and Sawyer DB (2007) Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol 7:114-121.
5. Danesi R, Fogli S, Gennari A, Conte P, and Del Tacca M (2002) Pharmacokineticpharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 41:431-444.
6. Dresdale AR, Barr LH, Bonow RO, Mathisen DJ, Myers CE, Schwartz DE, d'Angelo T, and Rosenberg SA (1982) Prospective randomized study of the role of N-acetyl cysteine in reversing doxorubicin-induced cardiomyopathy. Am J Clin Oncol 5:657-663.
7. Fredenburg AM, Wedlund PJ, Skinner TL, Damani LA, Hider RC, and Yokel RA (1993) Pharmacokinetics of representative 3-hydroxypyridin-4-ones in rabbits: CP20 and CP94. Drug Metab Dispos 21:255-258.
8. Glickstein H, El RB, Link G, Breuer W, Konijn AM, Hershko C, Nick H, and Cabantchik ZI (2006) Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 108:3195-3203.
9. Green DA, Antholine WE, Wong SJ, Richardson DR, and Chitambar CR (2001) Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase. Clin Cancer Res 7:3574-3579.
10. Hasinoff BB, Hellmann K, Herman EH, and Ferrans VJ (1998) Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 5:1-28.
11. Hasinoff BB, Patel D, and Wu X (2003) The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radic Biol Med 35:1469-1479.
12. Herman EH, Zhang J, and Ferrans VJ (1994) Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats. Cancer Chemother Pharmacol 35:93-100.
13. Herman EH, Zhang J, Hasinoff BB, Chadwick DP, Clark JR Jr., and Ferrans VJ (1997) Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines. Cancer Chemother Pharmacol 40:400-408.
14. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
15. Jones RL, Swanton C, and Ewer MS (2006) Anthracycline cardiotoxicity. Expert Opin Drug Saf 5:791-809.
16. Keizer HG, Pinedo HM, Schuurhuis GJ, and Joenje H (1990) Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 47:219-231.
17. Kontoghiorghes GJ, Pattichis K, Neocleous K, and Kolnagou A (2004) The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr Med Chem 11:2161-2183.
18. Kwok JC and Richardson DR (2003) Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway. Mol Pharmacol 63:849-861.
19. Lebrecht D, Geist A, Ketelsen UP, Haberstroh J, Setzer B, and Walker UA (2007) Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol 151:771-778.
20. Legha SS, Wang YM, Mackay B, Ewer M, Hortobagyi GN, Benjamin RS, and Ali MK (1982) Clinical and pharmacologic investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity. Ann N Y Acad Sci 393:411-418.
21. Lescoat G, Chantrel-Groussard K, Pasdeloup N, Nick H, Brissot P, and Gaboriau F (2007) Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism. Cell Prolif 40:755-767.
22. Link G, Tirosh R, Pinson A, and Hershko C (1996) Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J Lab Clin Med 127:272-278.
23. Menna P, Recalcati S, Cairo G, and Minotti G (2007) An introduction to the metabolic determinants of anthracycline cardiotoxicity. Cardiovasc Toxicol 7:80-85.
24. Minotti G, Menna P, Salvatorelli E, Cairo G, and Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229.
25. Myers C, Bonow R, Palmeri S, Jenkins J, Corden B, Locker G, Doroshow J, and Epstein S (1983) A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol 10:53-55.
26. Oliveira PJ, Bjork JA, Santos MS, Leino RL, Froberg MK, Moreno AJ, and Wallace KB (2004) Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol 200:159-168.
27. Pilz J, Meineke I, and Gleiter CH (2000) Measurement of free and bound malondialdehyde in plasma by high-performance liquid chromatography as the 2,4-dinitrophenylhydrazine derivative. J Chromatogr B Biomed Sci Appl 742:315-325.
28. Porter JB, Morgan J, Hoyes KP, Burke LC, Huehns ER, and Hider RC (1990) Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice. Blood 76:2389-2396.
29. Richardson DR (2005) Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer. Curr Med Chem 12:2711-2729.
30. Saad SY, Najjar TA, and Al-Rikabi AC (2001) The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol Res 43:211-218.
31. Simunek T, Klimtova I, Kaplanova J, Mazurova Y, Adamcova M, Sterba M, Hrdina R, and Gersl V (2004) Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents. Eur J Heart Fail 6:377-387.
32. Simunek T, Klimtova I, Kaplanova J, Sterba M, Mazurova Y, Adamcova M, Hrdina R, Gersl V, and Ponka P (2005a) Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits. Pharmacol Res 51:223-231.
33. Simunek T, Sterba M, Holeckova M, Kaplanova J, Klimtova I, Adamcova M, Gersl V, and Hrdina R (2005b) Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits. Biometals 18:163-169.
34. Sterba M, Popelova O, Simunek T, Mazurova Y, Potacova A, Adamcova M, Guncova I, Kaiserova H, Palicka V, Ponka P, et al. (2007a) Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH). Toxicology 235:150-166.
35. Sterba M, Popelova O, Simunek T, Mazurova Y, Potacova A, Adamcova M, Kaiserova H, Ponka P, and Gersl V (2006) Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity. J Pharmacol Exp Ther 319:1336-1347.
36. Sterba M, Simunek T, Popelova O, Potacova A, Adamcova M, Mazurova Y, Holeckova M, and Gersl V (2007b) Early detection of anthracycline cardiotoxicity in a rabbit model: left ventricle filling pattern versus troponin T determination. Physiol Res 56:535-545.
37. van Dalen EC, van der Pal HJ, Caron HN, and Kremer LC (2006) Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev:CD005008.
38. Wallace KB (2007) Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc Toxicol 7:101-107.
39. Wood JC, Otto-Duessel M, Gonzalez I, Aguilar MI, Shimada H, Nick H, Nelson M, and Moats R (2006) Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl Res 148:272-280.
40. Wouters KA, Kremer LC, Miller TL, Herman EH, and Lipshultz SE (2005) Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 131:561-578.
41. Xu LJ, Jin L, Pan H, Zhang AZ, Wei G, Li PP, and Lu WY (2006) Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin. Acta Pharmacol Sin 27:1333-1339.
42. Xu X, Persson HL, and Richardson DR (2005) Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol 68:261-271.
43. Xu X, Sutak R, and Richardson DR (2008) Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking. Mol Pharmacol 73:833-844.
44. Yasumoto E, Nakano K, Nakayachi T, Morshed SR, Hashimoto K, Kikuchi H, Nishikawa H, Kawase M, and Sakagami H (2004) Cytotoxic activity of deferiprone, maltol and related hydroxyketones against human tumor cell lines. Anticancer Res 24:755-762.
45. Yokel RA, Fredenburg AM, Meurer KA, and Skinner TL (1995) Influence of lipophilicity on the bioavailability and disposition of orally active 3-hydroxypyridin-4-one metal chelators. Drug Metab Dispos 23:1178-1180.
46. Yu Y, Wong J, Lovejoy DB, Kalinowski DS, and Richardson DR (2006) Chelators at the cancer coalface: desferrioxamine to triapine and beyond. Clin Cancer Res 12:6876-6883.